Phreesia (NYSE:PHR) Insider Evan Roberts Sells 1,810 Shares

Phreesia, Inc. (NYSE:PHR) insider Evan Roberts sold 1,810 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $16.38, for a total value of $29,647.80. Following the sale, the insider directly owned 832,822 shares in the company, valued at approximately $13,641,624.36. This represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Evan Roberts also recently made the following trade(s):

• On Friday, January 16th, Evan Roberts sold 6,268 shares of Phreesia stock. The shares were sold at an average price of $16.36, for a total value of $102,544.48.
• On Thursday, January 8th, Evan Roberts sold 6,317 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total transaction of $107,452.17.

Phreesia Stock Down 3.8%

PHR traded down $0.63 during trading on Tuesday, reaching $15.76. The company had a trading volume of 888,246 shares, compared to its average volume of 1,011,187. The company has a market cap of $950.23 million, a P/E ratio of -157.59 and a beta of 0.61. Phreesia, Inc. has a 12 month low of $15.41 and a 12 month high of $32.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. The business’s fifty day moving average price is $18.24 and its 200 day moving average price is $23.18.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The firm’s quarterly revenue was up 12.7% on a year-over-year basis. During the same period last year, the business posted ($0.25) earnings per share. Equities analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC raised its position in Phreesia by 243.6% during the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after acquiring an additional 71,553 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after acquiring an additional 3,000 shares during the period. Arcadia Investment Management Corp MI increased its stake in shares of Phreesia by 22.3% during the 2nd quarter. Arcadia Investment Management Corp MI now owns 113,470 shares of the company’s stock worth $3,229,000 after purchasing an additional 20,700 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Phreesia by 61.6% during the 2nd quarter. Acadian Asset Management LLC now owns 364,194 shares of the company’s stock worth $10,357,000 after purchasing an additional 138,877 shares during the last quarter. Finally, Boston Partners raised its holdings in shares of Phreesia by 165.1% in the 2nd quarter. Boston Partners now owns 130,060 shares of the company’s stock valued at $3,702,000 after purchasing an additional 81,006 shares during the period. 92.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. DA Davidson increased their price objective on Phreesia from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Mizuho decreased their price target on shares of Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, December 10th. BMO Capital Markets initiated coverage on shares of Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective on the stock. Finally, Canaccord Genuity Group lowered their price target on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, December 9th. Seventeen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.